However, several preclinical studies using a murine glioma model [30, 31] demonstrated that OX40-OX40L activation was related to a better prognosis and prolonged survival by agonistic OX40 antibody therapy through reverse intracranial T cell exhaustion. The gene discussed is TNFSF4; the disease is glioma.